Aldeyra's Dry Eye Drug Reproxalap Rejected by FDA for Third Time

LEXINGTON, MA – March 17, 2026

Aldeyra Therapeutics saw its stock value evaporate Tuesday after the U.S. Food and Drug Administration (FDA) once again rejected its promising dry eye disease treatment, reproxalap. The regulatory body issued a Complete Response Letter (CRL), its third for the drug, citing a failure to prove the drug's effectiveness, sending the company's shares plummeting by over 70% and casting serious doubt on the future of its lead product candidate.

The FDA's Verdict: A Question of Efficacy

In the CRL, the FDA stated that Aldeyra's New Drug Application (NDA) had "a lack of substantial evidence" and "failed to demonstrate efficacy in adequate and well controlled studies." The agency was particularly critical of the "inconsistency of study results," which it said raised "serious concerns about the reliability and meaningfulness of the positive findings."

This rejection marks a significant and painful setback for the Lexington-based biotechnology company, as it is the third time the FDA has denied reproxalap for this indication. Previous CRLs were issued in November 2023 and April 2025, both pointing to insufficient efficacy data. Following the April 2025 rejection, Aldeyra conducted an additional dry eye chamber trial which successfully met its primary endpoint for ocular discomfort. The company resubmitted its NDA in June 2025, buoyed by these results.

However, the positive chamber study was contrasted by a concurrent late-stage field trial that did not meet its primary endpoint. This juxtaposition of outcomes appears to be the crux of the FDA's "inconsistency" concern, concluding that the "totality of evidence from the completed clinical trials does not support the effectiveness of the product."

Notably, the FDA did not raise any safety or manufacturing issues, consistent with prior reviews. In a surprising move, the agency did not recommend that Aldeyra conduct additional clinical trials. Instead, the FDA suggested the company "explore the reasons for failure in certain trials" and "identify populations or certain conditions in which reproxalap may be effective." This points toward a path of deep data re-analysis rather than a costly and time-consuming new clinical program.

Market Meltdown and A Precarious Path Forward

The market's reaction to the news was swift and brutal. Aldeyra's stock (Nasdaq: ALDX) collapsed, falling approximately 74% to $1.09 by the day's end, wiping out more than $200 million in market capitalization. Trading volume surged to around 10 million shares, nearly ten times its daily average, as investors rushed to offload the stock.

The financial fallout extends beyond the immediate stock price. Aldeyra has an exclusive option agreement with pharmaceutical giant AbbVie for reproxalap, which includes a potential $100 million milestone payment contingent upon FDA approval. This repeated regulatory failure now places that crucial payment, and the partnership itself, in jeopardy.

Despite the devastating blow, Aldeyra reported having $70 million in cash and equivalents as of the end of 2025, which it projects will fund operations into 2028. The company's immediate strategy hinges on a planned Type A meeting with the FDA. Aldeyra stated it intends to "expeditiously request" the meeting, which is typically held within 30 days of the request, to "understand the actions needed for NDA approval."

"To the thousands of American and Canadian patients who participated in our clinical trials... I want to assure you that we will work with urgency to support the FDA in enabling market access," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, in a press release. He emphasized reproxalap's unique profile as potentially "the only drug with clinical activity within minutes of administration."

A Crowded Field for Dry Eye Relief

Dry eye disease is a common and often chronic condition affecting millions of people worldwide, creating a significant market for effective treatments. Patients often experience discomfort, redness, and visual disturbances that can impact their quality of life. The current treatment landscape, however, is characterized by medications that can take weeks or months to show even modest improvement.

Reproxalap's key differentiator was its potential for rapid action. This promise of near-instant relief represented a significant potential advantage in a crowded market that includes established products like AbbVie's Restasis, Novartis's Xiidra, and Bausch + Lomb's Miebo. The market has seen a flurry of activity, with recent approvals for VEVYE and MIEBO in 2023 and TRYPTYR in 2025.

With a robust pipeline of other investigational drugs from competitors like Palatin Technologies and Sylentis in various stages of development, the bar for new entrants is exceptionally high. For a new drug to succeed, it must demonstrate not only efficacy but also a clear and consistent benefit over existing options. The FDA's repeated rejection of reproxalap underscores the difficulty of meeting this standard, particularly in a condition like dry eye disease where clinical trial results can be notoriously variable.

The company's challenge now is to carve out a viable path from its existing, albeit inconsistent, clinical data. The FDA's suggestion to identify specific patient populations or conditions where the drug might be effective offers a sliver of hope. This could involve a complex post-hoc analysis of trial data to find a subgroup of patients who responded more consistently to the treatment. While this approach avoids the expense of new trials, it is a difficult analytical hurdle. Aldeyra's ability to successfully navigate its upcoming FDA meeting and present a compelling new analysis of its data will be critical in determining whether reproxalap has any future in treating dry eye disease.